Cancer Biomarkers Market Analysis 2018 With Leading Players Like BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.

As highlighted by Coherent Market Insights in its latest report on the market. Growing prevalence and incidence of various types of cancer coupled with increasing need for early diagnosis of cancers are the major factors driving growth of global cancer biomarkers market over the forecast period.

Continuous research and development and technology advancements in cancer biomarkers had led to introduction of better and affordable biomarkers in the field of clinical diagnosis.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/175

In February 2018, researchers at Georgetown-Lombardi Comprehensive Cancer Center, identified biomarkers, which can use liquid biopsies to predict response to cancer treatment and help in identifying increasingly specific subsets of GI cancers to make treatment decisions.

According to the data published in the European Journal of Breast Health, in October 2017, body fluid tests can be used for early detection of new or recurrent breast cancer. This new approach includes tissue testing and body fluid analysis of individuals diagnosed with breast cancer, for more effective cancer treatment.

Moreover, manufacturers are focusing on developing new cancer biomarkers, which would aid in early diagnosis of cancers and are used for oncology research studies. For instance, in November 2016, Oxford Cancer Biomarkers Ltd. introduced ColoTox test for predicting risk of toxicity with cancer chemotherapy tests. In December 2015, Olink Bioscience introduced Proseek Multiplex Oncology II96x96: 92 human protein biomarker panel for oncology research.

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/175

The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies.

For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in emerging economies. However, high cancer treatment cost and unfavorable reimbursement policies for cancer biomarker may hinder the growth of cancer biomarkers market.

Detailed Segmentation:

Global Cancer Biomarkers Market, By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers

Global Cancer Biomarkers Market, By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers

Global Cancer Biomarkers Market, By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/175

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.